Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Forty Seven Inc (FTSV)

Forty Seven Inc (FTSV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,933,704
  • Shares Outstanding, K 42,276
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,370 K
  • 60-Month Beta 3.53
  • Price/Sales 97.40
  • Price/Cash Flow N/A
  • Price/Book 10.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.70
  • Number of Estimates 5
  • High Estimate -0.61
  • Low Estimate -0.83
  • Prior Year -0.56
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.29 +41.65%
on 01/13/20
49.50 -7.60%
on 01/17/20
+10.04 (+28.12%)
since 12/17/19
3-Month
5.53 +727.12%
on 10/23/19
49.50 -7.60%
on 01/17/20
+39.60 (+644.95%)
since 10/17/19
52-Week
5.53 +727.12%
on 10/23/19
49.50 -7.60%
on 01/17/20
+30.54 (+200.92%)
since 01/17/19

Most Recent Stories

More News
Forty Seven Announces 2020 Strategic Priorities and Expected Milestones

-- Registration-Enabling Programs in MDS and DLBCL On-Track; Initiation of Phase 3 ENHANCE Trial in MDS and Phase 3 Trial in DLBCL Expected in 1Q and 2Q 2020 --

FTSV : 45.74 (+11.15%)
Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000 shares of common stock, including 729,000...

MS : 57.51 (+1.90%)
FTSV : 45.74 (+11.15%)
Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock...

MS : 57.51 (+1.90%)
FTSV : 45.74 (+11.15%)
Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock

Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock. All of the...

MS : 57.51 (+1.90%)
FTSV : 45.74 (+11.15%)
Biotech Industry Focusing on Growing Demand for Lyophilized Injectable Drugs

There are so many paths that R&D is taking in the ongoing fight against cancer. New drugs, new therapies and new techniques are developed to help researchers and practitioners across all cancer sub-markets....

CNSP : 4.33 (-2.91%)
DTIL : 10.68 (-3.70%)
FTSV : 45.74 (+11.15%)
DERM : 19.16 (+0.03%)
VTGN : 0.73 (+5.22%)
Forty Seven Reaches Analyst Target Price

In recent trading, shares of Forty Seven Inc have crossed above the average analyst 12-month target price of $21.50, changing hands for $30.43/share. When a stock reaches the target an analyst has set,...

FTSV : 45.74 (+11.15%)
Avadel Pharmaceuticals Appoints Dr. Mark McCamish to its Board of Directors

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating narcolepsy, announced today the appointment...

FTSV : 45.74 (+11.15%)
AVDL : 7.63 (-0.52%)
Forty Seven, Inc. Announces Foundational Preclinical Data Supporting the Development of FSI-174 in Combination with Magrolimab as a Novel All Antibody Conditioning Regimen for Hematopoietic Stem Cell Transplantation

-- Expect to Initiate Phase 1 Clinical Trial in Healthy Volunteers in First Quarter of 2020 --

FTSV : 45.74 (+11.15%)
Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS --

FTSV : 45.74 (+11.15%)
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

PTH : 96.32 (-0.02%)
PBE : 57.18 (-0.40%)
XBI : 96.27 (-0.83%)
CNCR : 23.43 (-0.60%)
DXCM : 230.79 (-1.54%)
CLVS : 9.85 (+3.96%)
BIIB : 285.50 (-0.22%)
PTI : 1.96 (+1.55%)
AQST : 4.10 (-0.97%)
FTSV : 45.74 (+11.15%)
ARKG : 35.05 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade FTSV with:

Business Summary

Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition...

See More

Key Turning Points

2nd Resistance Point 53.04
1st Resistance Point 49.39
Last Price 45.74
1st Support Level 42.20
2nd Support Level 38.66

See More

52-Week High 49.50
Last Price 45.74
Fibonacci 61.8% 32.70
Fibonacci 50% 27.51
Fibonacci 38.2% 22.33
52-Week Low 5.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar